Featured Research

from universities, journals, and other organizations

Less commonly prescribed antibiotic may be better for bloodstream infections

Date:
August 16, 2012
Source:
American Society of Nephrology (ASN)
Summary:
Hundreds of thousands of Americans develop bloodstream infections every year. Vancomycin was the most commonly prescribed antibiotic in dialysis patients for treating certain bloodstream infections, but cefazolin was 38% better than vancomycin at preventing hospitalizations and deaths from these infections. Cefazolin was also 48% better at preventing sepsis.

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Related Articles


When Staphylococcus aureus bacteria gain access to a patient's bloodstream, the infection then becomes life threatening. Antibiotics can often cure this infection, but without any antibiotic treatment, more than 80% of patients with bloodstream infections are likely to die. But what's the most appropriate antibiotic to use?

Kevin Chan, MD (Fresenius Medical Care North America and Massachusetts General Hospital) and his colleagues compared the effectiveness of various antibiotics at preventing hospitalization and death from bloodstream infection. They reviewed more than 500,000 blood culture results from their chronic kidney disease database, looking for methicillin-sensitive strains of S. aureus bloodstream infection. They also identified when physicians used vancomycin or cefazolin to treat these infections. Vancomycin is often perceived as the better antibiotic because it has broad coverage against many strains of bacteria; however, other factors like the antibiotic's killing power and tissue penetration are also important factors in selecting the best treatment.

Among the major findings:

• 56% of patients remained on vancomycin after blood culture results reported S. aureus bacteria were susceptible to cefazolin, while only 17% were treated with cefazolin.

• Cefazolin-treated patients experienced a 38% lower rate of hospitalization and death compared with vancomycin-treated patients.

• Cefazolin-treated patients also had a 48% lower rate of sepsis, which is the most serious form of bloodstream infection.

"I think the data suggest there is an opportunity to improve outcomes for patients through appropriate antibiotic selection," said Dr. Chan.

Study co-authors include H. Shaw Warren, MD, Ravi Thadhani, MD (Massachusetts General Hospital); David J.R. Steele, MD, Jeffrey L. Hymes, MD, Franklin Maddux, MD (Fresenius Medical Care North America); and Raymond Hakim, MD, PhD


Story Source:

The above story is based on materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.


Journal Reference:

  1. K. E. Chan, H. S. Warren, R. I. Thadhani, D. J. R. Steele, J. L. Hymes, F. W. Maddux, R. M. Hakim. Prevalence and Outcomes of Antimicrobial Treatment for Staphylococcus aureus Bacteremia in Outpatients with ESRD. Journal of the American Society of Nephrology, 2012; DOI: 10.1681/ASN.2012010050

Cite This Page:

American Society of Nephrology (ASN). "Less commonly prescribed antibiotic may be better for bloodstream infections." ScienceDaily. ScienceDaily, 16 August 2012. <www.sciencedaily.com/releases/2012/08/120816201443.htm>.
American Society of Nephrology (ASN). (2012, August 16). Less commonly prescribed antibiotic may be better for bloodstream infections. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2012/08/120816201443.htm
American Society of Nephrology (ASN). "Less commonly prescribed antibiotic may be better for bloodstream infections." ScienceDaily. www.sciencedaily.com/releases/2012/08/120816201443.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins